Crossing the divide: a longitudinal study of effective treatments for people with autism and attention deficit hyperactivity disorder across the lifespan

Declan Murphy,1* Karen Glaser,2 Hannah Hayward,1 Hanna Eklund,1 Tim Cadman,1 James Findon,1 Emma Woodhouse,3 Karen Ashwood,3 Jennifer Beecham,4 Patrick Bolton,5 Fiona McEwen,3,5 Ellie Wilson,1 Christine Ecker,1 Ian Wong,6 Emily Simonoff,5 Ailsa Russell,7 Jane McCarthy,8 Eddie Chaplin,1 Susan Young1 and Philip Asherson3

1Sackler Institute for Translational Neurodevelopment and Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, King’s College London, London, UK
2Institute of Gerontology, King’s College London, London, UK
3Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London, UK
4London School of Economics and Political Science, London, UK
5Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King’s College London, London, UK
6Department of Pharmacology and Pharmacy, University of Hong Kong, Pok Fu Lam, Hong Kong
7Department of Psychology, University of Bath, Bath, UK
8St Andrew’s Healthcare, Northampton, UK

*Corresponding author declan.murphy@kcl.ac.uk

Declared competing interests of authors: Declan Murphy has received research funding from Shire (Basingstoke, UK) and leads the European Union (EU) Innovative Medicines Initiative consortium EU Autism Interventions – a Multicentre Study for Developing New Medications that receives funding from both the EU and the European Federation of Pharmaceutical Industries and Associations. Ian Wong received a research grant from the European Commission, Hong Kong Research Grant Council and Janssen-Cilag Ltd (High Wycombe, UK) on research to investigate the safety of antipsychotic drugs and attention deficit hyperactivity disorder treatments. In addition, Ailsa Russell has a patent Authors Copyright – Treatment Manual Cognitive–Behavioural Therapy for Obsessive–Compulsive Disorder in Autism Spectrum Disorder pending. Susan Young has received honoraria for consultancy, travel, educational talks and/or research from the Cognitive Centre of Canada, Janssen Pharmaceutical (Raritan, NJ, USA), Eli Lilly (Indianapolis, IN, USA), Novartis (Frimley, UK), HB Pharma (Søborg, Denmark), Flynn Pharma (Stevenage, UK) and Shire. Philip Asherson has received honoraria for consultancy, travel, educational talks and/or research from Janssen Pharmaceutical, Eli Lilly, Novartis, HB Pharma, Flynn Pharma and Shire.
Scientific summary

Background

Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) both frequently persist into adolescence and young adulthood. However, there are few clinical services that support those with these disorders through adulthood. Research into the needs of young adults with an ASD or ADHD (and their carers) is important in order to design effective care programmes, but little is known about the service use and needs of these groups as they reach adolescence and transition to adulthood.

Research questions

1. What are the needs of affected individuals and their carers and are these met by health services?
2. Are people with ADHD and ASD already in contact with clinical services recognised and treated by the services?
3. Can we improve the diagnosis of ADHD and ASD by clinical services?
4. Can we improve the treatment of ADHD and ASD by clinical services?

Methods

The research comprised findings from four different work packages within this study over 5 years, from 2009 to 2013.

We (1) interviewed >180 affected individuals (and their families) with a confirmed diagnosis of ASD and/or ADHD, (2) screened for ASD and ADHD in approximately 1600 patients currently in receipt of clinical services in community medical (general practice) and mental health services (including general adult, forensic and prison settings) and (3) surveyed general practitioner (GP) prescribing to 5651 ASD individuals across the UK (as prescribing in ADHD has already been reported). Finally, we tested the effectiveness of (1) new ASD diagnostic interview measures in 169 twins, 145 families and 150 non-twins, (2) a magnetic resonance imaging-based diagnostic aid in 40 ASD individuals, (3) psychological treatments in 46 ASD individuals and (4) the feasibility of e-learning in 28 clinicians.

Results

The needs of affected individuals and their carers

Young people with ASD and ADHD have very significant needs as they transition through adolescence and young adulthood. A major contributor to this is associated mental health symptoms and/or ongoing educational and other functional impairments related to the ‘core disorder’. However, the additional/residual mental health problems (e.g. depression and anxiety) in ASD and ADHD are mostly undiagnosed (and untreated) by clinical services. Furthermore, the largest determinant of service provision is age and not severity of symptoms (e.g. in ADHD each 1-year increase in a young person’s age reduces the odds of being seen by services by 38%). This leads to a carer burden that is similar to looking after somebody with a traumatic brain injury or dementia.

Implications

Needs-led services are required that can both identify individuals with the ‘core symptoms’ of ASD and ADHD and treat their residual symptoms and associated conditions such anxiety and depression.
Are people with ADHD and ASD already in contact with clinical services recognised and treated?
Clinical services have a relatively high prevalence of people with ASD and ADHD, but these people are mainly unrecognised. Furthermore, these (unrecognised) individuals are functionally more impaired, have a higher rate of suicide attempts and spend longer periods in seclusion.

Overall, costs for both disorders are mainly borne by education and social care services – with much less accounted for by physical (and especially mental) health services. Finally, as individuals with ADHD and ASD grew older, mental health service costs reduce very significantly.

Implications
As individuals ‘transition’, their contact with treatment and support services reduces significantly. It is essential to increase diagnostic awareness and service provision.

Can we aid the diagnosis of ADHD and ASD by clinical services?
We took the pragmatic decision to adapt existing instruments (rather than developing completely new ones). In addition, relatively easy-to-use instruments for screening/diagnosing ADHD already exist. Hence, as a first step, we focused on ASD by testing the utility of the Development and Well-Being Assessment (DAWBA) and Strengths and Difficulties Questionnaire (SDQ) for diagnosing the core disorder and for identifying associated mental health symptoms, respectively.

The DAWBA performed well in our study of children and it has the potential to be a useful tool in community settings. In addition, the SDQ is a valid way to screen for comorbid anxiety disorders, depression and ADHD in adults with ASD.

In the next study, we explored the effect that changes to clinical diagnostic practice [as recommended in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)] would have on affected individuals. We found that DSM-V is a relatively insensitive measure of ASD in young adults compared with alternatives that are currently used in the UK [such as International Classification of Diseases, Tenth Edition (ICD-10)]. This is noteworthy as ICD-10 is about to be revised – and if similar approaches are adopted in International Classification of Diseases, Eleventh Edition, to those now used in DSM-V, or if DSM-V is adopted in the UK as a service ‘gatekeeper’, then many affected individuals with ASD could be excluded from services.

We therefore next determined if, in young adults, we could establish proof of concept that new advances in brain imaging provide objective measures that may help categorise young adults with ASD and/or ADHD. We could correctly classify 85% of all cases overall at a sensitivity and specificity as high as 90% and 80%, respectively.

Implications
Interview-based tools can help to diagnose the core disorder and associated symptoms in ASD; and there is proof of concept for the potential utility of brain biomarkers to help aid classification of ASD and ADHD in young adults.

Can we improve the treatment of ADHD and ASD?
In other parts of this programme, we found very high rates of associated mental health symptoms in people with ASD (e.g. depression and anxiety). However, relatively few individuals had been diagnosed with these symptoms by their GPs, and although approximately one-third of individuals with ASD received at least one psychotropic drug prescription, these were mostly for stimulants, antiepileptic drugs and mood stabilisers, and antipsychotics. Furthermore, as people aged prescribing rates for risperidone remained high (whereas others decreased).
Our pilot study on the effectiveness of cognitive–behavioural therapy (CBT) treatment was comparable to clinical trials of obsessive–compulsive disorder (OCD) in people without ASD. Unexpectedly, however, anxiety management (AM) training was also effective in bringing about a reduction in OCD symptoms.

Implications

1. Those who are prescribed antipsychotics are (relatively) unlikely to be taken off them.
2. People with ASD and ADHD are often not prescribed appropriate medications to treat common mental health symptoms.
3. AM training may allow more people to be treated (and at lower cost) for OCD in ASD, as it can be provided more simply and with a lower degree of staff expertise, than CBT.

Conclusions

As individuals ‘transition’ their contact with treatment and support services reduces significantly. Needs-led services are required, which can both identify individuals with the ‘core symptoms’ of ASD and ADHD and treat their residual symptoms and associated conditions.

Future work

To test our new diagnostic measures and treatment approaches in larger controlled trials.

Trial registration

This trial is registered as ISRCTN87114880.

Funding

Funding for this study was provided by the Programme Grants for Applied Research programme of the National Institute for Health Research.
Programme Grants for Applied Research

ISSN 2050-4322 (Print)
ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Programme Grants for Applied Research journal
Reports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme
The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report
The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0606-1045. The contractual start date was in August 2007. The final report began editorial review in August 2013 and was accepted for publication in July 2017. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk